⌘K

byHone Systems Hone

MENU

Market Intelligence

Timely disclosures Statutory filings News Filing Briefings Threads Shared themes

Komori×Hone Systems

Put AI to work in your business.Hone Systems builds AI into your day-to-day operations and keeps it running. Everything we build is yours.

Book 30 minutes →About Hone

What Komori does

Loading

HomeWatch Notifications

Phase III Development of Lorcaserin for Dravet Syndrome | Shared theme

⌘K

byHone Systems Hone

MENU

Market Intelligence

Timely disclosures Statutory filings News Filing Briefings Threads Shared themes

Komori×Hone Systems

Put AI to work in your business.Hone Systems builds AI into your day-to-day operations and keeps it running. Everything we build is yours.

Book 30 minutes →About Hone

What Komori does

ONE-WAYDated event · through FY2021

Phase III Development of Lorcaserin for Dravet Syndrome

A lorcaserin development program involving a U.S. Phase III clinical trial for Dravet syndrome, which received FDA orphan drug designation.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2021-Q2 →Last written FY2021

Directionhelps1 helps · 0 hurts · 0 flat

Loading

HomeWatch Notifications